Systemic lupus erythematosus (SLE) is the form of the disease that most people are referring to when they say "lupus." The word "systemic" means the disease can affect many parts of the body. The symptoms of SLE may be mild or serious. Although SLE usually first affects people between the ages of 15 and 45 years, it can occur in childhood or later in life as well.
In the ever-perilous autoimmune disease world of systemic lupus erythematosus (SLE or lupus), up to 60% of adult patients and 80% of children will develop lupus nephritis (LN), and up to half of those will move on to end-stage renal disease.
Researchers across Europe have delved into the DNA methylation patterns in CD4+ T-cells of psoriasis and psoriatic arthritis (PsA) patients, unveiling potential new biomarkers for these conditions. Their study suggests that these unique profiles could serve as both diagnostic and prognostic tools, although further validation is needed for real-world clinical application.
Scientists at CeMM, Max Perutz Labs, and St. Anna Children's Cancer Research Institute in Vienna have achieved a significant advancement in the research of rare immune system disorders.
Researchers trained machine learning (ML) models to analyze RNA molecular signatures in patients’ blood.
Researchers described the preclinical profile of JT002, a novel and orally bioavailable small molecule inhibitor of the NLRP3 inflammasome.
COVID-19 can increase the risk of various autoimmune diseases; however, this risk appears to be mitigated by vaccination against COVID-19.
Chandra Mohan, Hugh Roy and Lillie Cranz Cullen Endowed Professor of biomedical engineering, is reporting the first use of the powerful imaging mass cytometry (IMC) to examine the kidneys of patients with lupus (systemic lupus erythematosus), an autoimmune disease that can affect multiple organs and become fatal, and to diagnose lupus nephritis (LN) in those patients.
Researchers explore the role of self-extracellular nucleic acids in diseases like stroke, multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease.
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem involvement. Systemic sclerosis (SSc) or scleroderma is another rheumatic autoimmune disease that affects blood vessels, skin, and visceral organs.
A recent study published in Frontiers in Medicine described anti-post-translational modification (PTM) antibodies in patients with autoimmune-mediated and cholestatic liver diseases (AILD).
Study investigated if patients with systemic autoimmune rheumatic diseases (SARDs) have a reduced immunological response.
The Lupus Research Alliance is pleased to announce the 2023 recipients of the Career Development and Postdoctoral Awards to Promote Diversity in Lupus Research.
Researchers identify patient groups at a higher risk of death due to COVID-19 among adults who received a second booster dose in England.
Recurrent bouts of systemic lupus erythematosus, marked by the body's immune system attack of its own tissues, closely tracked with measurable upticks in growth in the gut of a certain species of bacteria.
Researchers assessed immune resilience (IR) metrics in individuals across diverse infectious and non-infectious models.
Treatment efficacy for a broad range of chronic diseases does not differ depending on patients' comorbidities, according to a new study publishing June 6th in the open access journal PLOS Medicine by David McAllister of the University of Glasgow, UK, and colleagues.
Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis.
A team from Peking Union Medical College Hospital in Beijing, China, have explored changes in the characteristics, treatment, and 5-year survival for SLE-associated PAH in the last decade, and possible reasons for survival change.
Janus kinase inhibitors (JAKi) and biologics are the cornerstone of modern treatment for rheumatoid arthritis (RA). But there have been concerns over long-term side effects.
Rheumatic and musculoskeletal diseases (RMDs) include over 200 diseases that affect over 120 million Europeans of all ages.